ABNOM
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
References
O le Q-switched Nd:YAG laser ua lauiloa e togafitia lelei nevus o Ota ma tulaga faapena. Na matou faia se suʻesuʻega e vaʻai ai pe faʻafefea ona galue le laser high-fluence 1064 nm Q-switched Nd:YAG i luga o nofoaga Monokolia i nofoaga e le masani ai, e aunoa ma le faʻafefe o le paʻu. Sa matou suʻesuʻeina le 61 tagata mamaʻi ma nei mea, suʻesuʻeina le aofaʻi o le 70 faʻamaʻi. O le afa o faʻamaʻi na togafitia i le laser, ae o isi na le toe togafitia mo faʻatusatusaga. Na matou iloiloina fa'ai'uga e fa'aaoga ai se fua ma se masini e ta'ua o le Mexameter® e fua ai le maualuga o le melanin. Na tulitatao tagata maʻi mo le averesi o 14 masina i le vaega o togafitiga ma 18 masina i le vaega o le mataʻituina. I le faaiuga o le suʻesuʻega, na matou maua ai ni eseesega taua i le fua faʻatatau ma le maualuga o le melanin i le va o vaega o loʻo togafitia ma le le togafitia, faʻatasi ai ma le faʻaogaina o le laser e faʻaalia ai taunuuga sili atu. O le high-fluence Q-switched Nd:YAG leisa, e aunoa ma le fa'amumuina o le pa'u, na fa'amaonia lelei ma saogalemu mo le togafitia o nei fa'ailoga Monokolia e le masani ai.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
Na matou suʻesuʻeina le aoga ma le saogalemu o le faʻaaogaina o se togafitiga faʻapitoa laser mo ABNOM , ma vaʻavaʻai i mea e ono aʻafia ai le lelei o le galue. Na matou vaʻavaʻai i le 110 tagata mamaʻi na maua ABNOM ma maua i le va o le lua ma le iva togafitiga laser. Na matou iloa e sili atu le lelei o le togafitiga i le umi na fai ai, ae le lelei i gasegase matutua. E sili atu le aoga i tagata mamaʻi e mama le paʻu (ituaiga III) ma vaega laiti na aʻafia (itiiti ifo i le 10 cm2) . O le maua o le ma'i ma'i fa'atasi ma le ABNOM na fa'aletonu ai le togafitiga. O le lanu po'o le numera o vaega na a'afia e foliga mai e leai se eseesega. E tusa ma le 10% o gasegase na maua ni lanu pogisa ina ua uma togafitiga. O togafitiga muamua na maua ai ni taunuuga lelei. O tagata mama'i matutua e pa'u'u le pa'u ma pa'epa'e pogisa e sili atu ona maua ni vaega pogisa pe a uma togafitiga. Mo tagata mama'i e maua i le ABNOM ma le melasma, e sili atu le fa'aogaina o le laser e maualalo le malosi e 'alofia ai le fa'aleagaina o le melasma.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ Togafiti
E seasea fesoasoani mea pa'epa'e. E le pei o le melasma, e mafai ona faʻaleleia le ABNOM ile togafitiga laser ma tuʻu e aveese e aunoa ma le toe faia. O togafitiga fa'a laser e mafai ona faia 10 i le 20 taimi e togafitia ai le ABNOM.
#QS1064 laser